M&A / Deals Eli Lilly bets on recombinases in $2.25bn Profluent R&D pact Pharmaceutical TechnologyEli Lilly and Profluent will harness AI to discover and develop recombinases for precise, large-scale gene editing.Read full story pharminent April 29, 2026 (Last updated: April 29, 2026) Pharmaceutical Technology Eli Lilly and Profluent will harness AI to discover and develop recombinases for precise, large-scale gene editing. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: The strategic investments expanding CDMO capabilities for HPAPIs and ADCsNext: Generic of Novo’s GLP-1 arrives in Canada, a ‘test case for the world’ Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
